OPKO Health, Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
OPKO Health, Inc. (OPK) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $0 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-06.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2021-02-18
- OPKO Health, Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- OPKO Health, Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-12-31 was $0.00.
- OPKO Health, Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-09-30 was $0.00.
- OPKO Health, Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-06-30 was $0.00.
- OPKO Health, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2019 was $50.85M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 | $0.00 derived: sum of 2 quarters · filed 2021-02-18 | $0.00 derived: sum of 3 quarters · filed 2021-02-18 | $0.00 derived: sum of 4 quarters · filed 2021-02-18 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-18 | $0.00 derived: sum of 2 quarters · filed 2021-02-18 | $0.00 derived: sum of 3 quarters · filed 2021-02-18 | $50.85M 10-K · filed 2021-02-18 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-07-31 | $50.85M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $50.85M 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $50.85M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |